# Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

> **NCT02446444** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Sydney** · enrollment: 802 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Conventional NSAA
- **DRUG:** LHRHA
- **RADIATION:** External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)

## Key facts

- **NCT ID:** NCT02446444
- **Lead sponsor:** University of Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-03
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 802 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446444, "Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02446444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*